MSH2 and Lynch syndrome: According to the Prospective Lynch Syndrome Database (PLSD), the cumulative cancer risks by age 70 are estimated at 71.9% for MLH1, 74.5% for MSH2, 46.3% for MSH6, and 21.7% for PMS2 mutation carriers (Vasen et al., 2007; Prospective Lynch Syndrome Database, 2025).